On the occasion of the Brain Awareness Week, the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) launch the RETHINKING Alzheimer's disease White Paper, calling for change in the detection and diagnosis of Alzheimer's disease. About Alzheimer's disease Alzheimer’s disease (AD), the most common form of [...]
Every three seconds someone develops dementia and for most of these individuals this will be as a result of Alzheimer’s disease, the leading cause. Alzheimer's is a relentless neurodegenerative condition which robs people of their memories, their independence, their relationships, and ultimately, their lives. On 24 January 2023, the European Brain Council (EBC), in collaboration [...]
Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]
The launch event of the RETHINKING Alzheimer's disease White Paper, calling for change in Alzheimer's care, will take place virtually on 24 January 2023 at 12:30 - 14:00. About Alzheimer's disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause [...]
The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is [...]
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health needs. It represents between 60% and 70% of the dementia cases. It is still diagnosed too late when the symptoms become evident as the disease progresses. AD is now portrayed as continuum consisting of 3 stages: [...]
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late, when the symptoms become more evident as the disease progresses. AD is now portrayed as a continuum [...]
Through RETHINKING Alzheimer’s disease (AD), the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are joining forces with the ambition of improving Alzheimer’s disease care pathway and the lives of people living with it. Officially launched on 29 April 2022, the project kicked off its operational activities with [...]